Eslovàquia - eslovac - ŠÚKL (Štátny ústav pre kontrolu liečiv)

herbacos recordati s.r.o., Česká republika - kyselina acetylsalicylová - 07 - analgetica, antipyretica

Eslovàquia - eslovac - ŠÚKL (Štátny ústav pre kontrolu liečiv)

herbacos recordati s.r.o., Česká republika - kyselina acetylsalicylová, kombinácie s výnimkou psycholeptík - 07 - analgetica, antipyretica

Unió Europea - eslovac - EMA (European Medicines Agency)

shionogi b.v. - naldemedine tosilate - zápcha - lieky na zápchu, periférne antagonisty opiátových receptorov - rizmoic je indikovaný na liečbu závislosti od opiátov-indukovanej zápcha (oic) u dospelých pacientov, ktorí v minulosti boli liečení s preháňadlo.

Eslovàquia - eslovac - ŠÚKL (Štátny ústav pre kontrolu liečiv)

herbacos recordati s.r.o., Česká republika - propiverín - 73 - spasmolytica

Unió Europea - eslovac - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatické nádory - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Unió Europea - eslovac - EMA (European Medicines Agency)

eli lilly nederland b.v. - tadalafil - hypertenzia, pľúca - urologika - adultstreatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity (see section 5. Účinnosť bola preukázaná v prípade idiopatickej pah (ipah) a pah súvisiacej s ochorením ciev kolagénu. paediatric populationtreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (pah) classified as who functional class ii and iii.

Unió Europea - eslovac - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - prostatické nádory - endokrinná terapia - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Unió Europea - eslovac - EMA (European Medicines Agency)

pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - antineoplastické činidlá - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.

Unió Europea - eslovac - EMA (European Medicines Agency)

pierre fabre medicament - binimetinib - melanóm - antineoplastické činidlá - binimetinib v kombinácii s encorafenib je indikovaný na liečbu dospelých pacientov s unresectable alebo metastatickým melanóm s braf v600 mutácie.

Unió Europea - eslovac - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - antineoplastické činidlá - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris je indikovaný na liečbu dospelých pacientov s relapsed alebo žiaruvzdorné cd30+ hodgkinovým lymfómom (hl):v nadväznosti na asct, orfollowing aspoň dve predchádzajúce terapie pri asct alebo multi-agent chemoterapia nie je možnosť liečby. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.